search
Back to results

Deep Brain Stimulation in Treatment Refractory Depression (DBSTRD)

Primary Purpose

Major Depressive Disorder

Status
Terminated
Phase
Phase 1
Locations
Belgium
Study Type
Interventional
Intervention
ITP Stimulation
CI/BNST stimulation
No stimulation
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring Deep Brain Stimulation, Major Depressive Disorder, Psychosurgery, Electrical stimulation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Major depressive disorder, severe, unipolar type, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity.
  • 17-item Hamilton Depression Rating Scale (HDRS) score of at least 19.
  • Global Assessment of Function (GAF) score of 45 or less.
  • A recurrent (>4 episodes) or chronic (episode duration >2 years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal ideation or a history of previous suicide attempts or other self-injurious behavior).
  • Failure to respond to:

    • adequate trials (>6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes AND;
    • adequate trials (>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) AND;
    • an adequate trial of Electroconvulsiontherapy (ECT) (>6 bilateral treatments) AND;
    • adequate relapse prevention by antidepressant medication or maintenance ECT or an adequate trial of individual psychotherapy.
  • Age ≥18 - ≤65 years.
  • Able to comply with the operational and administrative requirements of participation in the study ; able to comply with the questionnaires and the protocol.
  • Able to give written informed consent.
  • Either drug-free or on a stable drug regimen for at least 6 weeks at the time of entry into the study.
  • Good general health.
  • Candidates may have undertaken additional trials of potentially beneficial novel combinations of medication and psychotherapy, or they may have undertaken trials of novel interventions lacking definitive evidence of efficacy in severe depression (e.g., light therapy, herbal therapy, transcranial magnetic stimulation, vagal nerve stimulation).

Exclusion Criteria:

  • Current or past non-affective psychotic disorder.
  • Any current clinically significant neurological disorder or medical illness affecting brain function.
  • Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
  • Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation or significant cardiac or other medical risk factors for surgery.
  • Current or unstably remitted substance abuse.
  • Pregnancy and women of childbearing age not using effective contraception.
  • History of severe personality disorder, especially cluster B.
  • Imminent risk of suicide (based on the judgment of the investigators)
  • Present participation in another clinical trial

Sites / Locations

  • UZ Leuven

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

CI/BNST stimulation on

CI/BNST vs stimulation off

ITP stimulation on

CI/BNST vs ITP vs stimulation off

Arm Description

randomized, double blind, 1 week crossover

randomized, double blind, two month crossover

Outcomes

Primary Outcome Measures

Change from baseline in depressive symptoms as measured by the 17-item Hamilton Depression Rating Scale
The time frame is an approximation as evaluation is performed after each crossover phase. The time interval between baseline and evaluation depends on the time required for optimisation of DBS parameters.

Secondary Outcome Measures

Montgomery- Asberg Depression Rating Scale (MADRS)
Inventory for Depressive Symptoms, Self-Report (IDS-SR)
Global measures of illness severity and improvement:the clinician-rated Clinical Global Impressions - Severity (CGI-S) and Clinical Global Impressions - Improvement (CGI-I) scales, and the patient-rated Patient Global Impressions (PGI-S and PGI-I)
Global Assessment of Function (GAF)
patient-rated Symptom CheckList (SCL-90)
Cognitive function: Rey Auditory Verbal Learning Test; Trailmaking A & B, Stroop Test, Rey-Osterrieth complex figure test ; Wisconsin Card Sorting Test; Standard Progressive Matrices of Raven; Digit Span Test; Word Fluency Test
Hopelessness: using the Beck Hopelessness scale
Hamilton Anxiety Rating Scale (HARS)
Young Mania Rating Scale (YMRS)
Side Effects Questionnaire (SEQ)

Full Information

First Posted
January 8, 2013
Last Updated
July 15, 2015
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT01921543
Brief Title
Deep Brain Stimulation in Treatment Refractory Depression
Acronym
DBSTRD
Official Title
Electrical Stimulation of the Internal Capsule/Grey Matter and Inferior Thalamic Peduncle for Treatment-refractory Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Terminated
Why Stopped
Patient inclusion was very tedious and slower than expected. (7 patients in 5 years)
Study Start Date
January 2005 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Medtronic

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main aim of this trial was to investigate whether patients suffering from treatment refractory- Major Depressive Disorder (MDD) can benefit from DBS (Deep Brain Stimulation) in the brain areas known as inferior thalamic peduncle (ITP) and/or Capsula Interna/Bed nucleus of the stria terminalis (CI/BNST)
Detailed Description
This study aims to investigate the effect of deep brain stimulation (DBS)in major depressive disorder (MDD). After implantation of the DBS system, the effects of deep brain stimulation in ITP and CI/BNST will be evaluated. The design of the study consists of two consecutive crossover phases, interspaced with 2 optimalisation episodes. After a period of optimalisation of CI/BNST stimulation parameters, patients will be randomised in two groups. Half of the group of patients will receive stimulation in CI/BNST. The other half will not. After one week both groups will switch conditions during a period of one week. This will give an idea of the effects of stimulation in CI/BNST on the outcome measures. Outcome measures will be evaluated after each week. After this first crossover patients will continue to an optimalisation phase of ITP stimulation parameters. A second crossover will then follow. The effects of ITP stimulation, CI/BNST stimulation and no stimulation will be compared. In this phase patients will again be randomised to receive one of the six possible combinations of three consecutive periods of two months for the three different stimulation conditions (ITP stimulation, CI/BNST stimulation and no stimulation). Evaluations of outcome measures will be performed by blinded evaluators. This design will limit the duration of periods in which these severly ill patients are not stimulated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
Deep Brain Stimulation, Major Depressive Disorder, Psychosurgery, Electrical stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CI/BNST stimulation on
Arm Type
Experimental
Arm Title
CI/BNST vs stimulation off
Arm Type
Experimental
Arm Description
randomized, double blind, 1 week crossover
Arm Title
ITP stimulation on
Arm Type
Experimental
Arm Title
CI/BNST vs ITP vs stimulation off
Arm Type
Experimental
Arm Description
randomized, double blind, two month crossover
Intervention Type
Device
Intervention Name(s)
ITP Stimulation
Intervention Description
Model 7428 Kinetra® Neurostimulator Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead Model 3387 DBSTM Brain Lead Model 7482-51 Extension Model 7482-66 Extension Model 7482-95 Extension Model 7436 AccessTM Therapy Controller Model 3628 Dual Screener TM Model 8840 N'Vision
Intervention Type
Device
Intervention Name(s)
CI/BNST stimulation
Intervention Description
Model 7428 Kinetra® Neurostimulator Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead Model 3387 DBSTM Brain Lead Model 7482-51 Extension Model 7482-66 Extension Model 7482-95 Extension Model 7436 AccessTM Therapy Controller Model 3628 Dual Screener TM Model 8840 N'Vision
Intervention Type
Device
Intervention Name(s)
No stimulation
Primary Outcome Measure Information:
Title
Change from baseline in depressive symptoms as measured by the 17-item Hamilton Depression Rating Scale
Description
The time frame is an approximation as evaluation is performed after each crossover phase. The time interval between baseline and evaluation depends on the time required for optimisation of DBS parameters.
Time Frame
up to 14 months
Secondary Outcome Measure Information:
Title
Montgomery- Asberg Depression Rating Scale (MADRS)
Time Frame
up to 14 months
Title
Inventory for Depressive Symptoms, Self-Report (IDS-SR)
Time Frame
up to 14 months
Title
Global measures of illness severity and improvement:the clinician-rated Clinical Global Impressions - Severity (CGI-S) and Clinical Global Impressions - Improvement (CGI-I) scales, and the patient-rated Patient Global Impressions (PGI-S and PGI-I)
Time Frame
up to 14 months
Title
Global Assessment of Function (GAF)
Time Frame
up to 14 months
Title
patient-rated Symptom CheckList (SCL-90)
Time Frame
up to 14 months
Title
Cognitive function: Rey Auditory Verbal Learning Test; Trailmaking A & B, Stroop Test, Rey-Osterrieth complex figure test ; Wisconsin Card Sorting Test; Standard Progressive Matrices of Raven; Digit Span Test; Word Fluency Test
Time Frame
up to 14 months
Title
Hopelessness: using the Beck Hopelessness scale
Time Frame
up to 14 months
Title
Hamilton Anxiety Rating Scale (HARS)
Time Frame
up to 14 months
Title
Young Mania Rating Scale (YMRS)
Time Frame
up to 14 months
Title
Side Effects Questionnaire (SEQ)
Time Frame
up to 14 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Major depressive disorder, severe, unipolar type, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity. 17-item Hamilton Depression Rating Scale (HDRS) score of at least 19. Global Assessment of Function (GAF) score of 45 or less. A recurrent (>4 episodes) or chronic (episode duration >2 years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal ideation or a history of previous suicide attempts or other self-injurious behavior). Failure to respond to: adequate trials (>6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes AND; adequate trials (>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) AND; an adequate trial of Electroconvulsiontherapy (ECT) (>6 bilateral treatments) AND; adequate relapse prevention by antidepressant medication or maintenance ECT or an adequate trial of individual psychotherapy. Age ≥18 - ≤65 years. Able to comply with the operational and administrative requirements of participation in the study ; able to comply with the questionnaires and the protocol. Able to give written informed consent. Either drug-free or on a stable drug regimen for at least 6 weeks at the time of entry into the study. Good general health. Candidates may have undertaken additional trials of potentially beneficial novel combinations of medication and psychotherapy, or they may have undertaken trials of novel interventions lacking definitive evidence of efficacy in severe depression (e.g., light therapy, herbal therapy, transcranial magnetic stimulation, vagal nerve stimulation). Exclusion Criteria: Current or past non-affective psychotic disorder. Any current clinically significant neurological disorder or medical illness affecting brain function. Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI). Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation or significant cardiac or other medical risk factors for surgery. Current or unstably remitted substance abuse. Pregnancy and women of childbearing age not using effective contraception. History of severe personality disorder, especially cluster B. Imminent risk of suicide (based on the judgment of the investigators) Present participation in another clinical trial
Facility Information:
Facility Name
UZ Leuven
City
Leuven
State/Province
Vlaams-Brabant
ZIP/Postal Code
3000
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Deep Brain Stimulation in Treatment Refractory Depression

We'll reach out to this number within 24 hrs